Under construction – not a live service
Sign in
Taking people in ItalyPhase 3

Lower-dose radiotherapy for early-stage Hodgkin lymphoma after a good PET scan response

Compares 20 Gy with 30 Gy radiotherapy in adults with Hodgkin lymphoma.

Plain-language title generated from the registry record
Registry title: PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma

Key facts

Where
Alessandria, Avellino, Aviano, Bergamo, Brescia, Cagliari, Candiolo, Catania, Cuneo, Florence, Genova, Latina, Milan, Novara, Padova, Palermo, Pavia, Perugia, Piacenza, Ravenna, Reggio Emilia, Roma, Rozzano, San Giovanni Rotondo, Siena, Terni, Torino, Treviso, Trieste, Udine, and Verona, ItalySee the 38 sites
Phase
Phase 3

Where in Italy

  • A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. EmatologiaAlessandria, ItalyNot yet recruiting
  • A.O.R.N. G Moscati - U.O.C. Ematologia e Terapie cellulari avanzateAvellino, ItalyNot yet recruiting
  • IRCCS Centro Riferimento Oncologico - S.O.C. Oncologia medica e dei tumori immuno-correlatiAviano, ItalyNot yet recruiting
  • ASST Papa Giovanni XXIII - S.C. EmatologiaBergamo, ItalyNot yet recruiting
  • Clinica Humanitas Gavazzeni - U.O. Oncologia MedicaBergamo, ItalyNot yet recruiting
  • ASST Spedali Civili - S.C. EmatologiaBrescia, ItalyNot yet recruiting
  • ARNAS "Brotzu" P.O. Businco - S.C. Ematologia e TMOCagliari, ItalyNot yet recruiting
  • I.R.C.C.S. Istituto di Candiolo - FPOCandiolo, ItalyNot yet recruiting
  • ARNAS Garibaldi - U.O.C. EmatologiaCatania, ItalyNot yet recruiting
  • A.O. S. Croce e Carle - S.C. EmatologiaCuneo, ItalyNot yet recruiting
  • A.S.L. Toscana Centro - SOC OncoematologiaFlorence, ItalyNot yet recruiting
  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di EmatologiaFlorence, ItalyNot yet recruiting
  • IRCCS Policlinico S. Martino - U.O. Ematologia e terapie cellulariGenova, ItalyNot yet recruiting
  • ASL Latina Ospedale S. Maria Goretti - UOC Ematologia con trapiantoLatina, ItalyNot yet recruiting
  • ASST Grande Ospedale Metropolitano Niguarda - S.C. EmatologiaMilan, ItalyNot yet recruiting
  • IRCCS Fondazione Istituto Nazionale Tumori - S.C. EmatologiaMilan, ItalyNot yet recruiting
  • A.O.U. Ospedale Maggiore della Carità - S.C.D.U. EmatologiaNovara, ItalyNot yet recruiting
  • A.O.U. di Padova - U.O.C. EmatologiaPadova, ItalyNot yet recruiting
  • I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1Padova, ItalyNot yet recruiting
  • A.O. Ospedali Riuniti Villa Sofia-Cervello - Divisione di EmatologiaPalermo, ItalyNot yet recruiting
  • IRCCS Fondazione Policlinico S. Matteo - S.C. Ematologia 1Pavia, ItalyNot yet recruiting
  • A.O. Ospedale S. Maria della Misericordia - EmatologiaPerugia, ItalyNot yet recruiting
  • AUSL di Piacenza Ospedale Guglielmo da Saliceto - U.O.C. Ematologia e centro trapiantiPiacenza, ItalyNot yet recruiting
  • AUSL di Ravenna Osp. S. Maria delle Croci - U.O.C. EmatologiaRavenna, ItalyNot yet recruiting
  • AUSL IRCCS Arcispedale S. Maria Nuova - S.C. EmatologiaReggio Emilia, ItalyNot yet recruiting
  • A.O.U. Policlinico Umberto I - U.O.C EmatologiaRoma, ItalyNot yet recruiting
  • A.O.U. Sant'Andrea - U.O.C. EmatologiaRoma, ItalyNot yet recruiting
  • Fondazione Policlinico Campus Bio-Medico - U.O.C. Ematologia e trapianto di cellule staminaliRoma, ItalyNot yet recruiting
  • IRCCS Humanitas - U.O. EmatologiaRozzano, ItalyNot yet recruiting
  • IRCCS Fondazione Casa Sollievo della Sofferenza - UOC Ematologia e Trapianto di Cellule Staminali EmatopoieticheSan Giovanni Rotondo, ItalyNot yet recruiting
  • A.O.U. Senese - U.O.C. EmatologiaSiena, ItalyNot yet recruiting
  • A.O. Santa Maria - S.C. OncoematologiaTerni, ItalyNot yet recruiting
  • A.O.U. Città della Salute e della Scienza di Torino - S.C. EmatologiaTorino, ItalyTaking people
  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia UTorino, ItalyNot yet recruiting
  • ULSS 2 Ospedale Ca' Foncello - U.O.C. EmatologiaTreviso, ItalyNot yet recruiting
  • A.S.U. Giuliano Isontina - S.C. EmatologiaTrieste, ItalyNot yet recruiting
  • A.S.U. Friuli Centrale - Clinica EmatologicaUdine, ItalyNot yet recruiting
  • A.O.U.I. di Verona - U.O.C. EmatologiaVerona, ItalyNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Fondazione Italiana Linfomi - ETS
Trial code
NCT07256158
Record updated
27 August 2026
Original description
The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD.Read full original descriptionShow less

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma: a Randomized, Phase III, Non-inferiority studY (PRIORITY Study)

The final analysis of GHSG HD11 study (not PET driven) showed that 30 Gy IFRT still remains the standard dose after 4 ABVD.

Early PET negativity might allow safe radiation de-escalation in patients achieving a metabolic complete response after 2 ABVD.

The aim of Priority trial is to explore whether radiotherapy could be safely deescalated to 20 Gy without loss of efficacy in patients treated with four cycles of ABVD who achieved complete metabolic response after the first two cycles.

Inclusion: Age ≥18 years; Histologically confirmed classical HL stage I, II unfavorable according to GHSG criteria; Patient with any nodal mass ≥ than 10 cm can be included; No previous treatment for Hodgkin lymphoma; ECOG performance status 0 to 2; Presence of FDG-avid lymphoma lesions on baseline PET scan; Subject understands and voluntarily signs the informed consent form approved by the Independent Ethics Committee (IEC), prior to the initiation of any screening or study-specific procedures; Adequate organ and marrow function as defined below:; absolute neutrophil count > 1.0 x109/L; platelet count > 75 x109/L; Total bilirubin < 2 mg/dl without a pattern consistent with Gilbert's syndrome; Aspartate Transaminase and Alanine Transaminase (AST/ALT) < 3.0 X institutional Upper Limits of Normality (ULN); Creatinine within normal institutional limits or creatinine clearance > 50 mL/min; Women of childbearing potential must agree to use a highly effective method of contraception (oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device) from the signature of informed consent until six months after the last dose of treatment; Men must agree to use a highly effective method of contraception (barrier contraception or abstinence, when this is in line with the usual lifestyle of the subject) from the signature of informed consent until six months after the last dose of treatment; Women of childbearing potential must have a negative serum pregnancy test at screening.

Exclusion: Pre-treatment with chemotherapy or radiation therapy; Active HBV and HCV infection; HIV seropositivity; Malignant disease within the last 5 years (excluding basal skin tumors and carcinoma in situ of the cervix); Significant history of neurologic, psychiatric, endocrinological, metabolic, immunologic, or hepatic disease that would preclude participation in the study or compromise ability to give informed consent; Hodgkin Lymphoma as "composite lymphoma" or nodular lymphocyte prevalence histological subtype; Patients who meet any of the following criteria are not eligible to enroll:; Stage II B- III- IV; Women who are pregnant or breast feeding; Absence of FDG-avid lymphoma lesions on baseline PET scan.

ClinicalTrials.gov NCT07256158